<p>在今天發佈的一份報告中，美國銀行證券的傑森·傑伯裏維持了對 Royalty Pharma 的買入評級，目標價為 62.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>根據 TipRanks 的數據，傑伯裏是一位五星級分析師，平均回報率為 18.9%，成功率為 61.32%。傑伯裏覆蓋醫療保健行業，專注於 BioMarin Pharmaceutical、Ionis Pharmaceuticals 和 Alkermes 等股票。</p>
<p>Royalty Pharma 的分析師共識為強烈買入，目標價共識為 59.43 美元。</p>

RPRX

醫療業 ETF - Vanguard

美國制藥 ETF - iShares

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

醫療業 ETF - SPDR

<p>美國銀行證券對 Royalty Pharma (RPRX) 維持買入評級，目標價為 62.00 美元。分析師 Jason Gerberry 是一位五星級分析師，平均回報率為 18.9%，他強調了 Royalty Pharma 的強烈買入共識和目標價共識為 59.43 美元。Gerberry 還覆蓋了其他醫療保健股票，如 BioMarin Pharmaceutical 和 Ionis Pharmaceuticals</p>

<p>In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma, with a price target of $62.00.</p>
<div class="lb-trans"><p>在今天發佈的一份報告中，美國銀行證券的傑森·傑伯裏維持了對 Royalty Pharma 的買入評級，目標價為 62.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.9% and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Alkermes.</p>
<div class="lb-trans"><p>根據 TipRanks 的數據，傑伯裏是一位五星級分析師，平均回報率為 18.9%，成功率為 61.32%。傑伯裏覆蓋醫療保健行業，專注於 BioMarin Pharmaceutical、Ionis Pharmaceuticals 和 Alkermes 等股票。</p>
</div><p>Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $59.43.</p>
<div class="lb-trans"><p>Royalty Pharma 的分析師共識為強烈買入，目標價共識為 59.43 美元。</p>
</div>

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

Tip Ranks

Royalty Pharma PLC - CL

美國銀行

拜瑪林制藥

Ionis制藥

阿爾凱默斯

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美國銀行證券維持對 Royalty Pharma（RPRX）的買入評級